TAP’s Prevacid PAP Is Available To Part D Beneficiaries; Bristol-Myers Squibb To Focus On Coalition Approach
This article was originally published in The Pink Sheet Daily
TAP extended its Prevacid prescription assistant program to Medicare drug plan enrollees whose household income is between 135% and 200% of the federal poverty level.
You may also be interested in...
Market share has stabilized but Amgen acknowledges that the TNF inhibitor “isn’t performing up to our expectations.”
Center for American Progress suggests pricing reforms for the 'next Administration' in lieu of legislation.